The Indian drug regulator has denied Dr Reddy's Laboratories the permission to conduct Phase-3 trials of Sputnik Light, a single dose COVID-19 vaccine, in India, news agency ANI has reported.
Sputnik Light demonstrated 79.4% efficacy, according to an analysis of data gathered 28 days after the shot was administered as part of Russia’s mass vaccination programme between December 2020 and April 2021, the vaccine’s developers said in a statement. Gamaleya Center also demonstrated during laboratory tests that Sputnik Light had proven effective against all new strains of the coronavirus, the statement said.
Meanwhile Sputnik V, a two dose vaccine developed by Russia'a Gamaleya Institute, has begun in some Indian cities.